The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year

1987

Stage

IPO | IPO

Total Raised

$21.6M

Date of IPO

3/27/1996

About GalaGen

Developing pharmaceuticals derived from dairy products and antibody-rich milk to treat gastrointestinal diseases. Antibodies are extracted from bovine milk or colostrum (milk produced by a cow for three days after a calf is born) in a manner that preserves active immunoglobulins. These immunoglobulins retain their anti-microbial activity when administered orally to humans. The company's bovine milk and colostrum-based products have shown significant efficacy in preventing major digestive tract infections. PRxO-IMMUNE was introduced in 1990 and is used to prevent diarrheal disease in newborn calves. As of September 1993, GalaGen was in clinical development of nine biopharmaceuticals for seven infectious conditions, including diarrhea in HIV-positive individuals and AIDS patients, duodenal ulcers, rotavirus infections, and hemolytic uremic syndrome. Also in development are three transgenic products: human lactoferrin, casein, and blood coagulation Factor IX. The company merged with ProCor in July 1992. Signed an agreement with Chiron in March 1995 to co-develop Helicobacter pylori antibodies.

GalaGen Headquarter Location

4001 Lexington Avenue North

Arden Hills, Minnesota, 55126,

United States

(612)481-2105

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

  • When was GalaGen founded?

    GalaGen was founded in 1987.

  • Where is GalaGen's headquarters?

    GalaGen's headquarters is located at 4001 Lexington Avenue North, Arden Hills.

  • What is GalaGen's latest funding round?

    GalaGen's latest funding round is IPO.

  • How much did GalaGen raise?

    GalaGen raised a total of $21.6M.

  • Who are the investors of GalaGen?

    Investors of GalaGen include Edgewater Funds, Pappajohn Capital Resources and Crescendo Ventures.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.